Clinical trials: Ferric Carboxymaltose
Iron Deficiency Anemia
Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia
The safety, tolerability, pharmacokinetics and pharmacodynamics of Z-213 will be investigated in patients with iron-deficiency anemia after administration of a single dose (100 mg, 500 mg, 800 mg or 1,000 mg iron).
- Trial name
- NCT02170311
- Testing
- Z-213
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Zeria Pharmaceutical
Iron Deficiency Anemia
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
Iron deficiency anaemia (IDA) in postoperative patients with confirmed preoperative iron deficiency (ID) in a population with planned major surgery who need fast replenishment of iron as judged by the treating physician will be…
- Trial name
- IDA-II (NCT03817957)
- Testing
- Polyglucoferron, Ferric carboxymaltose, Ferrous Sulfate
- Where
- Germany
- Volunteers
- 187 people
- Sponsor
- Prof. Dr. Frank Behrens
Ferric Carboxymaltose, Heart Failure With Reduced Ejection Fraction
Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction
An open label,single-center, non-interventional prospective study with the aim on investigating the effect of intravenous ferric carboxymaltose in restoring iron status and reducing the risk of severe arrhythmic events in…
- Conditions
- Ferric Carboxymaltose, Heart Failure With Reduced Ejection Fraction, Arrhythmias, Cardiac
- Trial name
- RESAFE (NCT04974021)
- Testing
- Ferric carboxymaltose
- Where
- Greece
- Volunteers
- 106 people
- Sponsor
- Aristotle University Of Thessaloniki
Heart Failure With Normal Ejection Fraction, Iron-deficiency
Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction
This study aims to investigate the effects of treatment with intravenous ferric carboxymaltose on exercise tolerance measured as VO2peak in patients with HFpEF and iron deficiency, compared to placebo.
- Trial name
- IRON-HFpEF (NCT05477498)
- Testing
- Ferric carboxymaltose
- Sponsor
- Cantonal Hospital, Baselland
Pulmonary Hypertension, Iron Deficiency
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
Pulmonary hypertension (PH) is a condition characterized by elevated blood pressure in the pulmonary arteries. This leads to symptoms such as shortness of breath and a significantly reduced exercise capacity, resulting in a very…
- Trial name
- IRON-PH (NCT07359599)
- Testing
- Ferric Carboxymaltose (FCM), Sodium Chloride (NaCl) 0.9 %
- Where
- 7 sites in Belgium
- Volunteers
- 306 people
- Sponsor
- Ziekenhuis Oost-Limburg
Iron Deficiency, Anaemia
Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)
Investigation whether a switch from oral iron to intravenous ferric carboxymaltose can reduce dose requirements of erythropoiesis-stimulating agents (ESA) and improve Hb levels and iron status in adult patients with…
- Trial name
- NCT02232906
- Testing
- intravenous ferric carboxymaltose
- Where
- Argentina
- Volunteers
- 30 people
- Sponsor
- Hospital Aleman
Restless Legs Syndrome (RLS)
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
Treatment Phase I and II Primary Objective: To evaluate the efficacy and safety of FCM (750 mg dose x 2) for treatment of Restless Legs Syndrome (RLS) in patients with iron-deficiency anemia (IDA).
- Trial name
- NCT02826681
- Testing
- Injectafer® (Ferric Carboxymaltose - FCM)
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- American Regent, Inc.
Anemia, Iron Deficiency
Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery
Several studies using new forms of intravenous iron showed that it is effective in treating perioperative anemia in orthopedic and digestive surgery.
- Trial name
- FCAACS (NCT03759964)
- Testing
- Ferric carboxymaltose
- Where
- Lebanon
- Volunteers
- 194 people
- Sponsor
- St Joseph University, Beirut, Lebanon
GastroIntestinal Bleeding, Anemia
Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding
Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation.
- Trial name
- FIERCE (NCT05060731)
- Testing
- Oral iron supplementation, Intravenous iron supplementation
- Where
- Hungary
- Volunteers
- 570 people
- Sponsor
- University of Pecs
Blood Loss Anemia
Postoperative Replacement of Intraoperative Iron Losses
By performing a randomized, blinded placebo controlled exploratory trial we speculate that replacement of perioperative, bleeding-induced iron losses with ferric carboxymaltose immediately after the surgical procedure can…
- Trial name
- POREIIL (NCT03680456)
- Testing
- Ferric carboxymaltose, Crystalloid
- Where
- Austria
- Volunteers
- 134 people
- Sponsor
- Kepler University Hospital
Chronic Heart Failure, Iron Deficiency, Latent
The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)
Observational cohort randomized controlled study to study the influence of correction of ID by intravenous injection of ferric carboxymaltose (Ferinject®) on quality of life indicators, functional status in a cohort of patients…
- Trial name
- ID-HFpEF (NCT05793996)
- Testing
- Ferinject, Diet therapy
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Anemia
The Effect of Ferric Carboxymaltose on Hemoglobin and Blood Transfusion in Cardiac Surgery
Anemia after cardiac surgery is a vast phenomena. More than 70% of the patients who under went surgery represented with hemoglobin less than 8 mg/dl (the cutoff for blood transfusion) and more than 80% of the patients receives at…
- Trial name
- NCT02939794
- Testing
- Ferinject
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Myocardial Infarction, Acute
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to…
- Trial name
- INFERRCT (NCT05759078)
- Testing
- Ferinject, Sodium Chloride 0.9% Inj
- Where
- 43 sites in Poland
- Volunteers
- 1,000 people
- Sponsor
- Wroclaw Medical University